Candesartan and renal protection: more than blocking angiotensin type 1 receptor?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18854846.
- Also identified by DOI 10.1038/ki.2008.420.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chen et al. show that candesartan (Cand) displays an antioxidant action independent of angiotensin type 1 receptor (AT1R) blockade that translates into a superior renoprotection of chronic renal inflammation. The peculiarity of Cand in combining AT1R-blocking activity and an antioxidant action could have important theoretical implications for therapy.
Medical subject headings
- Benzimidazoles
- Kidney Diseases
- Tetrazoles